SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

07 Nov 2024 Evaluate
The revenue for the September 2024 quarter is pegged at Rs. 41062.00 millions, about 12.21% up against Rs. 36592.30 millions recorded during the year-ago period.A good growth in profit of 47.24% reported to Rs. 8077.60  millions over Rs. 5486.10 millions of corresponding previous quarter.Operating profit surged to 11473.70 millions from the corresponding previous quarter of 8608.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 41062.00 36592.30 12.21 82738.30 71548.70 15.64 146665.00 112588.30 30.27
Other Income 326.20 256.00 27.42 717.00 533.40 34.42 1067.30 912.60 16.95
PBIDT 11473.70 8608.40 33.28 23852.60 15936.00 49.68 35657.90 11739.20 203.75
Interest 175.50 153.20 14.56 311.00 315.00 -1.27 563.50 984.40 -42.76
PBDT 11298.20 8455.20 33.62 23541.60 15621.00 50.70 35094.40 10754.80 226.31
Depreciation 1457.70 1494.80 -2.48 2871.90 2895.30 -0.81 7247.50 5483.40 32.17
PBT 9840.50 6960.40 41.38 20669.70 12725.70 62.42 27846.90 5271.40 428.26
TAX 1762.90 1474.30 19.58 3700.30 2470.00 49.81 4586.00 1019.30 349.92
Deferred Tax 43.40 177.70 -75.58 88.90 166.20 -46.51 -254.50 60.40 -521.36
PAT 8077.60 5486.10 47.24 16969.40 10255.70 65.46 23260.90 4252.10 447.04
Equity 912.30 910.50 0.20 912.30 910.50 0.20 911.40 910.00 0.15
PBIDTM(%) 27.94 23.53 18.78 28.83 22.27 29.44 24.31 10.43 133.18

Lupin Share Price

2376.00 0.00 (0.00%)
04-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1960.00
Dr. Reddys Labs. 1160.65
Cipla 1450.00
Lupin 2376.00
Zydus Lifesciences 1118.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: